Lupin Ltd

Lupin Ltd., one of India’s leading pharmaceutical companies, has entered a strategic partnership with Gan & Lee Pharmaceuticals to launch a novel obesity drug in the Indian market. The collaboration aims to combine Lupin’s strong distribution network and regulatory expertise with Gan & Lee’s innovative formulation, addressing the growing prevalence of obesity and related metabolic disorders in India.

Pharmaceutical major Lupin Limited has announced a strategic expansion of its Contract Development and Manufacturing Organization (CDMO) operations through the establishment of a state-of-the-art oncology block at its Visakhapatnam facility. The move underscores the company’s ambition to enhance its global presence in specialty manufacturing and meet the rising demand for complex cancer therapies.

Lupin Limited, a prominent Indian pharmaceutical company, has introduced a generic version of liraglutide injection in the United States. This medication, marketed under the brand name Victoza by Novo Nordisk, is indicated for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. The launch signifies Lupin's strategic entry into the glucagon-like peptide-1 (GLP-1) receptor agonist market, a class of drugs experiencing increased demand. The U.S.

Pharmaceutical major Lupin has entered into a strategic partnership with Sandoz to market and distribute its biosimilar Ranibizumab in select global markets. Ranibizumab, a widely prescribed treatment for retinal disorders such as age-related macular degeneration and diabetic macular edema, represents a high-value segment within the ophthalmology therapeutics market. This collaboration combines Lupin’s manufacturing expertise with Sandoz’s extensive global commercial network, aiming to broaden patient access to advanced eye care solutions.

In a robust start to the fiscal year, pharmaceutical giant Lupin Ltd reported a 52% year-on-year rise in consolidated net profit, reaching Rs. 1,221 crore for the quarter ended June 2025. The stellar performance was driven by a strong uptick in U.S. generics sales, operational efficiencies, and favorable foreign exchange movement. Total revenue for the quarter stood at Rs. 5,289 crore, registering double-digit growth. The company also witnessed a significant margin expansion, underpinned by improved product mix and cost containment.

In a strategic move that underscores the growing significance of biosimilars in global healthcare, Indian pharmaceutical giant Lupin has entered into an exclusive partnership with Zentiva, a prominent European generics player, to market and distribute its proposed biosimilar version of certolizumab pegol. This collaboration positions both companies to tap into the lucrative European market for biologic therapies targeting autoimmune conditions.

Indian pharmaceutical equities plunged on June 17, as investor sentiment deteriorated following US President Donald Trump’s renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index dropped over 2%, marking it as the day’s worst-performing sector. With India being one of the largest exporters of generic drugs to the US, analysts fear a significant impact on margins, revenues, and forward guidance for key industry players. Major firms like Cipla, Dr.

Pharmaceutical major Lupin Ltd. has entered into a strategic license and supply agreement with Costa Rica-based SteinCares to commercialize its biosimilar ranibizumab in Latin America, excluding Mexico and Argentina. Under this collaboration, SteinCares will lead regulatory filings and distribution, while Lupin will retain responsibility for manufacturing. The move aligns with Lupin’s broader vision of increasing access to advanced biologic therapies in emerging markets.

Pharmaceutical major Lupin Ltd delivered a striking performance in the quarter ended March 31, 2025, with consolidated profit after tax (PAT) more than doubling to Rs 782 crore, fueled by new product launches and enhanced operational efficiencies. Sales climbed to Rs 5,562 crore in Q4, up from Rs 4,895 crore the previous year, reflecting sustained commercial momentum. For the full fiscal year 2024-25, Lupin posted a 71% surge in PAT to Rs 3,306 crore on revenues of Rs 22,192 crore, underlining the company’s successful strategic execution.